The p53 codon 72 polymorphism is associated with risk and early onset of breast cancer among Saudi women

Oncology Letters

Volumn 3, Issue 4, 2012, Pages 875-878

  Al Qasem, Abeer ^a   Toulimat, Mohamed ^b   Tulbah, Asma ^b   Elkum, Naser ^c,e   Al Tweigeri, Taher ^d   Aboussekhra, Abdelilah ^a  

^a Epidemiology and Scientific Computing   (Saudi Arabia)

^b Departments of Pathology   (Saudi Arabia)

^c Departments of Biostatistics   (Saudi Arabia)

^d KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^e Dasman Centre for Research and Treatment of Diabetes   (Kuwait)

Author keywords

Breast cancer; Early onset; P53; SNP72

Indexed keywords

ARGININE; PROLINE; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PATIENT; CANCER RISK; CODON; CONTROLLED STUDY; DISEASE ASSOCIATION; EXON; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE SEQUENCE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; SAUDI ARABIA; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84856934676     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.581     Document Type: Article

References (26)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Ezzat AA, Ibrahim EM, Raja MA, et al: Locally advanced breast cancer in Saudi Arabia: high frequency of stage III in a young population. Med Oncol 16: 95-103, 1999.
3. Elkum N, Dermime S, Ajarim D, et al: Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: the Saudi Arabia experience. BMC Cancer 7: 222, 2007.
4. Greenblatt MS, Bennett WP, Hollstein M and Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
5. Levine AJ and Oren M: The first 30 years of p53: growing ever more complex. Nat Rev Cancer 9: 749-758, 2009.
6. Pietsch EC, Humbey O and Murphy ME: Polymorphisms in the p53 pathway. Oncogene 25: 1602-1611, 2006.
7. Whibley C, Pharoah PD and Hollstein M: p53 polymorphisms: cancer implications. Nat Rev Cancer 9: 95-107, 2009.
8. Hartmann W, Digon-Sontgerath B, Koch A, et al: Phosphatidylinositol 3'-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Clin Cancer Res 12: 3019-3027, 2006.
9. Wei M, Grushko TA, Dignam J, et al: BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res 65: 10692-10699, 2005.
10. Toyama T, Zhang Z, Nishio M, et al: Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 9: R34, 2007.
11. Murphy ME: Polymorphic variants in the p53 pathway. Cell Death Differ 13: 916-920, 2006.
12. Felley-Bosco E, Weston A, Cawley HM, Bennett WP and Harris CC: Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am J Hum Genet 53: 752-759, 1993.
13. Li X, Dumont P, Della Pietra A, Shetler C and Murphy ME: The codon 47 polymorphism in p53 is functionally significant. J Biol Chem 280: 24245-24251, 2005.
14. He XF, Su J, Zhang Y, et al: Association between the p53 polymorphisms and breast cancer risk: meta-analysis based on case-control study. Breast Cancer Res Treat 130: 517-529, 2011.
15. Buyru N, Tigli H and Dalay N: P53 codon 72 polymorphism in breast cancer. Oncol Rep 10: 711-714, 2003.
16. Papadakis EN, Dokianakis DN and Spandidos DA: p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 3: 389-392, 2000.
17. Jee SH, Won SY, Yun JE, et al: Polymorphism p53 codon-72 and invasive cervical cancer: a meta-analysis. Int J Gynaecol Obstet 85: 301-308, 2004.
18. Alawadi S, Ghabreau L, Alsaleh M, et al: P53 gene polymorphisms and breast cancer risk in Arab women. Med Oncol 28: 709-715, 2011.
19. Dumont P, Leu JI, Della Pietra AC III, George DL and Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357-365, 2003.
20. Khadang B, Fattahi MJ, Talei A, Dehaghani AS and Ghaderi A: Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet 173: 38-42, 2007.
21. Tommiska J, Eerola H, Heinonen M, et al: Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 11: 5098-5103, 2005.
22. Xu Y, Yao L, Zhao A, et al: Effect of p53 codon 72 genotype on breast cancer survival depends on p53 gene status. Int J Cancer 122: 2761-2766, 2008.
23. Zhang Z, Wang M, Wu D, et al: P53 codon 72 polymorphism contributes to breast cancer risk: a meta-analysis based on 39 case-control studies. Breast Cancer Res Treat 120: 509-517, 2010.
24. Hu Z, Li X, Yuan R, Ring BZ and Su L: Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis. Breast Cancer Res Treat 120: 705-714, 2010.
25. Ma Y, Yang J, Liu Z, et al: No significant association between the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysis of 21 studies involving 24,063 subjects. Breast Cancer Res Treat 125: 201-205, 2011.
26. Francisco G, Menezes PR, Eluf-Neto J and Chammas R: Arg72Pro TP53 polymorphism and cancer susceptibility: A comprehensive meta-analysis of 302 case-control studies. Int J Cancer 129: 920-930, 2011.